Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Reduced Trial
Source : https://www.sciencedirect.com/science/article/pii/S2213177922007090?via=ihub
There is limited published information on outcome adjudication in heart failure (HF).The authors sought to compare investigator reports (IRs) to a Cli...
Conclusions: Investigator adjudication is an alternative to a CEC with similar accuracy and faster event accumulation. The use of granular (SCTI) criteria did not improve trial performance. Finally, our data suggest that consideration be given to broadening the HHF definition to include “for or with” worsening disease.
-
Cardiologist Connect3yrKey Points • Source: JACC Heart Failure • Conclusion: “In this study, the investigators had a similar accuracy in detecting treatment effect and HHF [first event hospitalization primarily for heart failure] events with comparable Show More
Recency of Heart Failure Hospitalization, Outcomes, and the Effect of Empagliflozin: An EMPEROR-Pooled Analysis
Source : https://www.sciencedirect.com/science/article/pii/S2213177923000732?via=ihub
Available online 20 February 2023 Author links open overlay panel a b c , , d e , , , , , , , k l , m n Show...
Conclusions: Patients with a recent HF hospitalization have a high risk of events. Empagliflozin reduced HF events regardless of HF hospitalization recency.
Clinical Study of Metabolic Parameters, Leptin and the SGLT2 Inhibitor Empagliflozin among Patients with Obesity and Type 2 Diabetes - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36901837/
Obesity is a major public health problem worldwide, and it is associated with many diseases and abnormalities, most importantly, type 2 diabetes. The visceral adipose tissue produces an immense variety...
Lessons learned: The EMMY trial shows that early use of the SGLT2 inhibitor empagliflozin after acute myocardial infarction (MI) improves natriuretic peptide levels and markers of cardiac function and structure supporting the use of Empagliflozin in HF related to a recent MI.
Metformin, Empagliflozin, and Their Combination Modulate Ex-Vivo Macrophage Inflammatory Gene Expression - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36902218/
Type-2 Diabetes Mellitus is a complex, chronic illness characterized by persistent high blood glucose levels. Patients can be prescribed anti-diabetes drugs as single agents or in combination depending on the...
Conclusions/Relevance: Findings from this study suggest that metformin and empagliflozin as single agents or in combination can directly modulate inflammatory gene expression in macrophages and upregulate the expression of their receptors.
Clinical profiling of end-stage heart failure with preserved ejection fraction: The National Readmission Database
Source : https://www.internationaljournalofcardiology.com/article/S0167-5273(23)00269-3/fulltext
Heart failure with preserved ejection is a heterogenous clinical syndrome with varying prognosis. * Using unsupervised machine learning algorithm, 4 clinical profiles were identified. 1) obese patients with sleep and...
Conclusion: End-stage HFpEF presents with different clinical profiles with varied upstream causes. This may help provide evidence toward the development of targeted therapies.